Biocompatible and biodegradable nanoparticles designed for proteinaceous
drugs absorption and delivery
    6.
    发明授权
    Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery 失效
    生物相容性和可生物降解的纳米粒子设计用于蛋白质药物的吸收和输送

    公开(公告)号:US5962566A

    公开(公告)日:1999-10-05

    申请号:US973863

    申请日:1998-05-07

    IPC分类号: A61K9/51

    摘要: The presently claimed invention comprises a biopolymer nanoparticle for drug delivery wherein the nanoparticle comprises a homogeneous blend of an aliphatic polyester polymer blended with a polyether, a lipophilic or polypeptide drug and a biocompatible cholesterol interacting agent for preserving the activity of the drug administered to the patient while at the same time controlling the release of the drug. Methods for making the homogeneous drug delivery nanoparticles are also disclosed.

    摘要翻译: PCT No.PCT / EP96 / 02878第 371日期1998年5月7日 102(e)日期1998年5月7日PCT PCT 1996年7月2日PCT公布。 出版物WO97 / 0202200 日本1997年1月23日本发明包括用于药物递送的生物聚合物纳米颗粒,其中纳米颗粒包含与聚醚共混的脂族聚酯聚合物,亲脂性或多肽药物和生物相容性胆固醇相互作用剂的均匀共混物,用于保持 同时施用于患者的药物同时控制药物的释放。 还公开了制备均匀药物递送纳米颗粒的方法。

    Process for controlled radical polymerization or copolymerization of
(meth)acrylic and vinyl monomers and (co)polymers obtained
    9.
    发明授权
    Process for controlled radical polymerization or copolymerization of (meth)acrylic and vinyl monomers and (co)polymers obtained 失效
    获得的(甲基)丙烯酸和乙烯基单体和(共)聚合物的受控自由基聚合或共聚方法

    公开(公告)号:US5767210A

    公开(公告)日:1998-06-16

    申请号:US827386

    申请日:1997-03-27

    CPC分类号: C08F4/00 C08F4/80

    摘要: This process is characterized by the fact that at least one of the said monomers is polymerized or copolymerized in bulk, solution, emulsion or suspension, at a temperature that can be as low as 0.degree. C., in the presence of an initiation system including: at least one compound generating radicals, other than bromofluorene, and at least one catalyst consisting of a complex of palladium in the 0 oxidation state, denoted by the following formula (I): Pd(0)L.sup.1 L.sup.2 L.sup.3 L.sup.4 in which each of L.sup.1, L.sup.2, L.sup.3 and L.sup.4, which are identical or different, denotes a ligand which may be a chiral ligand, which is chosen from PRR'R", P(OR)(OR')(OR"), NRR'R", ORR', SRR', SeRR', AsRR'R", SbRR'R", where each of R, R' and R" independently denotes a C.sub.1 -C.sub.14 alkyl group, optionally substituted, or an optionally substituted aromatic group, it being possible for at least two of these ligands to be joined to one another by one or more divalent radicals.

    摘要翻译: 该方法的特征在于,在起始系统存在下,至少一种所述单体在本体,溶液,乳液或悬浮液中在可低至0℃的温度下聚合或共聚,包括 :除了溴芴之外,至少一种产生自由基的化合物和至少一种由O型氧化态的钯络合物组成的催化剂,由下式(I)表示:Pd(0)L1L2L3L4,其中L1,L2 表示可以是手性配体的配体,其选自PRR'R“,P(OR)(OR')(OR”)(OR“),NRR'R” ,ORR',SRR',SeRR',AsRR'R“,SbRR'R”,其中R,R'和R“各自独立地表示任选取代的C 1 -C 14烷基或任选取代的芳族 这些配体中的至少两个可能通过一个或多个二价基团彼此连接。